- Home
- STEP vs EWTX Comparison
STEP vs EWTX Comparison
Compare STEP & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STEP | EWTX |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.7B |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | STEP | EWTX |
|---|---|---|
| Price | $42.96 | $45.40 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 6 |
| Target Price | ★ $71.00 | $39.00 |
| AVG Volume (30 Days) | ★ 1.7M | 1.6M |
| Earning Date | 05-21-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.98% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,993,603,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $26.41 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 69.69 | N/A |
| 52 Week Low | $38.85 | $12.31 |
| 52 Week High | $77.80 | $48.40 |
Technical Indicators
Market Signals| Indicator | STEP | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.49 | 64.21 |
| Support Level | $41.11 | $29.03 |
| Resistance Level | $49.24 | N/A |
| Average True Range (ATR) | 2.35 | 2.71 |
| MACD | 0.49 | 0.66 |
| Stochastic Oscillator | 60.29 | 74.16 |
Price Performance
Historical ComparisonAbout STEP StepStone Group Inc.
StepStone Group Inc operates as a fully integrated private markets solution provider. The company provides customized investment solutions and advisory and data services. It provides investment solutions in the areas of private equity, real estate, private debt, and infrastructure and real assets. The company consists of a single operating segment and a single reportable segment for accounting and financial reporting purposes.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.